RxDoctor Payments Data

John Hornick, MD

Family Medicine · West Chester, PANPI 1629284831

Payments from drug & device makers

$8,594in general payments, 2019–2025

Across 479 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$841
  • AstraZeneca$775
  • Boehringer Ingelheim$593
  • Pfizer$590
  • GSK$361
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$8,576100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,594 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$113,949
Medicare patients
516
Services billed
2,428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine30$187,348
OzempicSemaglutide68$74,533
EliquisApixaban70$61,290
JanuviaSitagliptin Phosphate33$30,282
JardianceEmpagliflozin21$28,645
Invega SustennaPaliperidone Palmitate11$26,769
FarxigaDapagliflozin Propanediol22$23,289
TrulicityDulaglutide11$10,760
Olanzapine OdtOlanzapine14$8,539
MyrbetriqMirabegron18$8,167
Rosuvastatin Calcium389$7,581
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$6,697
Breo ElliptaFluticasone/Vilanterol12$5,504
Depakote ErDivalproex Sodium12$5,320
Atorvastatin Calcium473$4,954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$194$187,34830 claims
Novo NordiskOzempic$841$74,53368 claims
PfizerEliquis, Paxlovid$590$64,026101 claims
Johnson & JohnsonInvega Sustenna, Risperdal$51$31,52622 claims
MerckJanuvia$171$30,28233 claims
Boehringer IngelheimJardiance$593$28,64521 claims
AstraZenecaFarxiga$775$23,28922 claims
GSKTrelegy Ellipta, Breo Ellipta$361$12,20124 claims
Lilly USA, LLCTrulicity$339$10,76011 claims
Astellas Pharma US IncMyrbetriq$213$8,16718 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$3,675396 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in West Chester

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →